High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)

By sjmartinez • April 29, 2025

Riddler SA, Moodie Z, Clark J, Yen C, Allen M, Furch BD, Lu H, Grant S, Mondal K, Anderson M, Maenza J, Lemos MP, Woodward Davis AS, Walsh SR, Sobieszczyk ME, Frank I, Goepfert P, Stephenson KE, Baden LR, Tieu HV, Keefer MC, McElrath MJ, Kublin JG, Corey L. High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302). Ann Intern Med. 2025 Apr 29. doi: 10.7326/ANNALS-24-02701. Epub ahead of print. PMID: 40294415.

Tags: Infectious Diseases, Publications

DASC-LOT Framework and S3 Metric: A Novel Evaluation and Benchmarking Method to Assess Initiation, Duration, and Spectrum of Antimicrobial Usage at Inpatient Hospital Settings

Goto M, Imai S, Cho H, Merchant JA, Goetz MB, Perencevich EN, Alexander B, Shi Q, Holcombe A, Livorsi DJ. DASC-LOT Framework and S3 Metric:[...]

Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions

Hermann JN, Kruger SE, Wodniak N, Holland J, Janosick V, Sanchez A, Zuniga-Moya JC, Brucker D, Torres B, Melo KM, Oliveros E, Kuran R, D'Assumpcao[...]

Structure and potential role of T6SS effector PdpC in Francisella tularensis intracellular lifestyle

Liu X, Clemens DL, Lee BY, Xia X, Fan H, Feng KY, Horwitz MA, Zhou ZH. Structure and potential role of T6SS effector PdpC in[...]